RHB-204 + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Mycobacterium Avium Complex Infection
Conditions
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
Trial Timeline
Dec 1, 2020 → Aug 28, 2023
NCT ID
NCT04616924About RHB-204 + Placebo
RHB-204 + Placebo is a phase 3 stage product being developed by RedHill Biopharma for Pulmonary Mycobacterium Avium Complex Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT04616924. Target conditions include Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Mycobacterium Avium Complex Infection were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04616924 | Phase 3 | Terminated |
Competing Products
20 competing products in Pulmonary Mycobacterium Avium Complex Infection